Biomarin Pharmaceutical (BMRN) Depreciation and Depletion (2010 - 2026)

Biomarin Pharmaceutical has disclosed Depreciation and Depletion across 17 years of filings, most recently posting $8.8 million for Q1 2026.

• Quarterly Depreciation and Depletion fell 37.59% year-over-year to $8.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.2 million (down 10.19% YoY) and the FY2025 annual result came in at $48.5 million, up 4.08% from the prior year.
• Depreciation and Depletion fell to $8.8 million in Q1 2026, from $13.2 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $14.1 million in Q1 2025 and troughed at $8.7 million in Q3 2022.
• A 5-year average of $10.8 million and a median of $10.6 million in 2025 frame the typical range for Depreciation and Depletion.
• Annual changes were most pronounced in 2023 — Depreciation and Depletion increased 22.99% — and 2026, when it slumped 37.59%.
• Tracing BMRN's Depreciation and Depletion over 5 years: stood at $8.7 million in 2022, then grew by 22.99% to $10.7 million in 2023, then gained by 8.41% to $11.6 million in 2024, then increased by 13.79% to $13.2 million in 2025, then slumped by 33.33% to $8.8 million in 2026.
• Business Quant data shows BMRN's Depreciation and Depletion at $8.8 million in Q1 2026, $13.2 million in Q4 2025, and $10.6 million in Q3 2025.